Kamada Launches Two Biosimilars in Israel
Kamada has launched Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, bringing its biosimilar portfolio to four. The company anticipates sales of approximately $4 million in 2026, $10 million in 2028, and $20 million to $25 million annually by 2030 from this portfolio in Israel and the MENA region.